Literature DB >> 25964579

Nuclear survivin expression in small cell lung cancer.

Yukihiro Yano1, Tomoyuki Otsuka2, Hiroshi Hirano3, Takeshi Uenami4, Akitoshi Satomi4, Muneyoshi Kuroyama4, Manabu Niinaka4, Tsutomu Yoneda4, Hiromi Kimura4, Masahide Mori4, Toshihiko Yamaguchi4, Soichiro Yokota4.   

Abstract

BACKGROUND/AIM: Little evidence exists regarding a relationship between survivin expression and prognosis in small cell lung cancer (SCLC). We investigated the relationship between survivin expression, clinical characteristics and prognosis in SCLC patients.
MATERIALS AND METHODS: We retrospectively reviewed medical records of study patients and analyzed their tumor sections using nuclear survivin labeling index (LI).
RESULTS: A significant correlation between nuclear survivin LI and clinical stage was found (p=0.012). In multivariate analysis, a significant association was found between survival and clinical stage (hazard ratio (HR)=2.09; 95 % confidence interval (CI)=1.08-4.31; p=0.027) but not between survival and nuclear survivin LI (HR=0.96; 95 % CI=0.91-1.02; p=0.2).
CONCLUSION: We did not find any positive relationship between nuclear survivin expression and survival in SCLC patients. Conversely, we found a positive relationship between clinical stage and nuclear survivin LI, which is considered to be useful in deciding treatment strategies. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Small cell lung cancer; immunohistochemistry; labeling index; nucleus; survivin

Mesh:

Substances:

Year:  2015        PMID: 25964579

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Survivin overexpression is potentially associated with pituitary adenoma invasiveness.

Authors:  Xiangyi Kong; Shun Gong; Lijuan Su; Xinqi Cheng; Honglei Li; Tingting You; Yanguo Kong
Journal:  Oncotarget       Date:  2017-11-10

2.  Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Rita Puskas; Andras Bikov; Peter Horvath; Zsofia Lazar; Laszlo Kunos; Reka Nagy; Gabriella Pinter; Gabriella Galffy
Journal:  Pathol Oncol Res       Date:  2021-04-30       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.